Abstract
Background: Previous studies reported that stress-induced phosphoprotein 1 (STIP1) can be secreted by hepatocellular carcinoma (HCC) cells and is increased in the serum of HCC patients. However, the therapy-monitoring and prognostic value of serum STIP1 in HCC remains unclear. Here, we aimed to systemically explore the prognostic significance of serum STIP1 in HCC.
Methods: A total of 340 HCC patients were recruited to this study; 161 underwent curative resection and 179 underwent transcatheter arterial chemoembolization (TACE). Serum STIP1 was detected by enzyme-linked immunosorbent assay (ELISA). Optimal cutoff values for serum STIP1 in resection and TACE groups were determined by receiver operating characteristic (ROC) analysis. Prognostic value was assessed by Kaplan-Meier, log-rank, and Cox regression analyses. Predictive values of STIP1 for objective response (OR) to TACE and MVI were evaluated by ROC curves and logistic regression.
Results: Serum STIP1 was significantly increased in HCC patients when compared with chronic hepatitis B patients or health donors (both P < 0.05). Optimal cutoff values for STIP1 in resection and TACE groups were 83.43 and 112.06 ng/ml, respectively. High pretreatment STIP1 was identified as an independent prognosticator. Dynamic changes in high STIP1 status were significantly associated with long-term prognosis, regardless of treatment approaches. Moreover, post-TACE STIP1 was identified as an independent predictor for OR, with a higher area under ROC curve (AUC-ROC) than other clinicopathological features. Specifically, pretreatment STIP1 was significantly increased in patients with microvascular invasion (MVI), and was confirmed as a novel, powerful predictor for MVI.
Conclusions: Serum STIP1 is a promising biomarker for outcome evaluation, therapeutic response assessment, and MVI prediction in HCC. Integration serum STIP1 detection into HCC management might facilitate early clinical decision making to improve the prognosis of HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide, with increasing incidence and mortality rates (1–3). Radical resection is considered the only curative approach for early-stage HCC. However, despite impressive innovations in surgical procedures, the overall survival (OS) of HCC patients remains unsatisfactory due to high incidence of recurrence or relapse after surgery (4–6). Nonetheless, for irresectable, intermediate-HCC patients, transcatheter arterial chemoembolization (TACE) has evolved as a recommended approach by the Barcelona Clinic Liver Cancer (BCLC) criteria to achieve stable clinical benefit in these patients (7, 8). Unfortunately, response rates are dramatically heterogeneous, and long-term prognosis also remains poor after TACE (9, 10). Therefore, identification of a reliable biomarker to assist pre-interventional stratification is urgently required.
Stress-induced phosphoprotein 1 (STIP1) was initially identified as an auxiliary partner for heat shock proteins (HSPs) 70 and 90 to modulate the function of HSPs by modulating their dimer structure (11). In addition to its role as a scaffold protein, STIP1 was also found to have a pivotal role in regulating transcription and intracellular signaling transduction, as well as cell proliferation and division (12–14). Consistently, accumulating evidences show that STIP1 is involved in several critical processes that mediate tumor progression including proliferation, migration, and invasion (15–18), indicating its necessity in the development of cancer. Conventionally, STIP1 was considered as a typical cytoplasmic protein due to its lack of transmembrane domain or trans-signal peptide (11). However, recent studies revealed that STIP1 could be secreted by several types of cancer cells, including HCC, and serves as a cytokine in regulating tumor progression (19–21), which strongly suggests serum STIP1 is a promising circulating biomarker for HCC. However, the clinical significance of serum STIP1 remains largely unknown.
Here, in the present study, we evaluated the prognostic value of pretreatment serum STIP1 and dynamic changes in STIP1 levels in HCC. In addition, we assessed the utility of serum STIP1 detection for predicting TACE response. Importantly, we also investigated the value of pretreatment STIP1 levels for predicting microvascular invasion (MVI).
Methods and Materials
Patients
Two independent cohorts of HCC patients were enrolled in the present study. Cohort I was recruited from January 2011 to December 2012 and included 161 HCC patients who received curative resection at Zhongshan Hospital as the resection group. All patients in the resection group were Barcelona Clinic Liver Cancer (BCLC) stage 0 or A. Cohort II was recruited from January to December 2014 and included a total of 179 patients who received TACE as the TACE group. All patients in the TACE group were BCLC stage B. Enrollment criteria were as follows (22): (1) definitive HCC diagnosis; (2) no prior anti-HCC treatment; (3) complete resection of all tumor lesions with the cut surface being free of cancer; (4) TACE treatment targeting intrahepatic lesions; and (5) availability of complete clinicopathological and follow-up data. Exclusion criteria were as follows: (1) Child-Pugh C or severe liver dysfunction; (2) receiving any treatment before enrollment; (3) suffering intrahepatic or extrahepatic metastases; (4) having history of any malignancy other than HCC; and (5) insufficient available data. HCC diagnosis in the resection group was based on histopathology examination, while diagnosis was based on imaging scans according to the American Association for the Study of Liver Disease guidelines in the TACE group (22). MVI was defined according to a previous study and was examined by senior pathologists (23). In addition, a total of 122 HDs and 55 patients with CHB without any sign of malignancy were enrolled as negative controls. Approval for the use of human subjects was obtained from the Research Ethics Committee of Zhongshan Hospital. Importantly, informed consent was obtained from every individual who participated in the study.
Follow-Up and Prognosis Evaluations
Post-treatment surveillance was performed according to our previous studies. Follow-up ended on December 2018. Time to recurrence (TTR), time to progression (TTP), and overall survival (OS) were set as end points of follow-up in present study (24). TTR was defined as the time interval between resection and intrahepatic recurrence or the date of the last follow-up. TTP was defined as the time interval between TACE and disease progression according to mRECIST or the date of the last follow-up (25). OS was defined as the interval between treatment and the death of any cause or last observation date.
Sample Collection and STIP1 Level Determination
Serum samples were collected from all patients enrolled at baseline (1 or 2 days before interventions) and 1 month after treatments as we did previously (22). STIP1 concentrations were determined by enzyme-linked immunosorbent assay (ELISA) using the Human STIP1 ELISA Kit (Cat: LS-F7598, LifeSpan, USA), according to the manufacturer's instructions. Samples were 2-fold diluted by PBS to avoid exceeding detection limit (>100 ng/ml). The optimal cutoff values of STIP1 in resection and TACE groups were determined by receiver operating characteristics curve analysis, and were set as 83.43 and 112.06 ng/ml, respectively.
Evaluation of Single TACE Response
Single TACE response evaluation was conducted 1 month after initial treatment according to our previous study (26). Contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) scans were conducted, and results were interpreted by senior, experienced radiologists in imaging diagnosis. Treatment responses were assessed based on 1.1 modified RECIST and patients were stratified as follows: complete response (CR, n = 0); partial response (PR, n = 136); stable disease (SD, n = 21); and progressive disease (PD, n = 22). CR and PR were further defined as objective response (OR) according to previous studies (27, 28).
Statistical Analysis
Statistical analysis was performed with SPSS 21.0 software (IBM, USA). Continuous variables are shown as mean ± standard error of the mean, and chi-squared test, Fisher's exact probability test, and Student's t-tests were conducted to determine significant differences between the groups. If the data were not homogeneous, the non-parametric Mann-Whitney U test was applied. Receiver operating characteristic curve analysis was conducted to assess the value of STIP1 level for predicting response to TACE and MVI presence in HCC. Prognostic values were evaluated via Kaplan-Meier curve analysis, log-rank tests, and Cox proportional hazard ratio models. Logistic regression analysis was performed to evaluate the significance of STIP1 in predicting response to TACE. A P-value of < 0.05 was considered statistically significant.
Results
Baseline Characteristics of HCC Patients Enrolled
Overall, 517 individuals were recruited in the present study (HCC, 340; chronic hepatitis B, 55; healthy donors, 122, Figure 1). Baseline characteristics are illustrated in Table 1. Mean age was 53.38 years for the resection group and 50.25 years for the TACE group, and 16.15% of patients in the resection group were female while 11.73% of patients in the TACE group were female. HBsAg positivity was 83.85% in the resection group and 89.39% in the TACE group. According to BCLC staging criteria, all patients who underwent resection were BCLC stage 0 or A, while all patients undergoing TACE were BCLC stage B.
Figure 1
Table 1
| Variables | Resection (n=161) | TACE (n=179) | |||||
|---|---|---|---|---|---|---|---|
| STIP1 ≤ 83.43 ng/ml | STIP1 > 83.43 ng/ml | P | STIP1 ≤ 112.06 ng/ml | STIP1 > 112.06 ng/ml | P | ||
| Sex | Female | 10 | 16 | 0.365 | 6 | 15 | 0.206 |
| Male | 65 | 70 | 68 | 90 | |||
| Age | ≤ 50 year | 29 | 36 | 0.680 | 30 | 52 | 0.235 |
| >50 year | 46 | 50 | 44 | 53 | |||
| HBsAg | Negative | 13 | 13 | 0.924 | 9 | 10 | 0.523 |
| Positive | 62 | 73 | 65 | 95 | |||
| ALT | ≤ 40 U/L | 47 | 52 | 0.775 | 45 | 61 | 0.716 |
| >40 U/L | 28 | 34 | 29 | 44 | |||
| AFP | ≤ 400 ng/ml | 60 | 61 | 0.184 | 46 | 58 | 0.355 |
| >400 ng/ml | 15 | 25 | 28 | 47 | |||
| Cirrhosis | No | 3 | 3 | 0.864 | 8 | 6 | 0.211 |
| Yes | 72 | 83 | 66 | 99 | |||
| Tumor size | ≤ 5 cm | 60 | 52 | 0.012 | 21 | 25 | 0.491 |
| >5 cm | 15 | 34 | 53 | 80 | |||
| Number | Single | 63 | 76 | 0.420 | Not applicable | ||
| Multiple | 12 | 10 | |||||
| MVI | Absent | 57 | 38 | <0.001 | Not applicable | ||
| Present | 18 | 48 | |||||
| Encapsulation | Complete | 60 | 51 | 0.005 | Not applicable | ||
| Incomplete | 15 | 35 | |||||
| Differentiation | I–II | 52 | 52 | 0.240 | Not applicable | ||
| III–IV | 23 | 34 | |||||
Correlation between clinicopathological parameters of patients enrolled.
HR, hazard ratio; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AFP, α-fetoprotein; STIP1, Stress Induced Phosphoprotein 1; MVI, microvascular invasion.
Serum STIP1 Was Elevated in HCC and Associated With Tumor Progression
Intermediate-HCC patients who received TACE showed the highest serum STIP1 levels, while early patients undergoing curative resection also had significantly higher STIP1 levels than CHB (P = 0.002) and HD (P < 0.001) individuals (Figure 2A). Interestingly, CHB patients also exhibited higher STIP1 levels than HDs. Further investigation indicated STIP1 levels showed a weak correlation with AFP level (r = 0.124, P = 0.022; Figure 2B). Moreover, we found patients with bigger tumor sizes (diameter over 5 cm) exhibited significantly higher serum STIP1 concentrations in both the resection (P = 0.003; Figure 2C) and TACE (P = 0.039; Figure 2D) groups. Together, our data demonstrated that serum STIP1 levels were elevated in HCC patients, and a higher concentration might indicate HCC progression.
Figure 2
Determination of Cutoff Value of Pretreatment Serum STIP1 for Predicting Prognosis in Resection and TACE Group
Pretreatment STIP1 levels were significantly higher in patients who encountered recurrence (P < 0.001) or death (P = 0.001, Figure 3A) in the resection group. Similarly, patients who experienced progression (P < 0.001) or death (P = 0.002) also exhibited significantly higher pretreatment STIP1 levels (Figure 3B). The above results indicated pretreatment STIP1 might act as a powerful tool for predicting prognosis in HCC. Because patients in the TACE group had significantly higher pretreatment STIP1 levels than the patients in the resection group, an independent cutoff value was set for these two groups to achieve the satisfactory performance of STIP1. Using receiver operating characteristic (ROC) curve analysis, 83.43 ng/ml was found to harbor the biggest Youden index when predicting recurrence in the resection group (sensitivity, 69.79%; specificity, 70.77%; Figure 3C), whereas 112.06 ng/ml was found to obtain the biggest Youden index when predicting progression in the TACE group (sensitivity, 63.69%; specificity, 77.27%). Therefore, these two values were set as cutoff values to stratify HCC patients into different pretreatment STIP1 states for subsequent investigations.
Figure 3
Prognostic Value of Pretreatment STIP1 Level in Resectable HCC
In the resection group, the median follow-up was 36.83 months (range, 1.0–94.0) for TTR and 68.45 months (range, 9.0–94.0) for OS. Patients with high pretreatment STIP1 (>83.43 ng/ml) had significantly shorter TTR (23.60 months vs. not reached, P < 0.001) and OS (47.33 months vs. not reached, P < 0.001) than patients with low pretreatment STIP1 (≤ 83.43 ng/ml) (Figure 3D). Consistently, patients with high pretreatment STIP1 had higher recurrence (77.91 vs. 38.67%) and death (67.44 vs. 33.33%) rates (Figure 3E). Cox regression analysis revealed that high pretreatment STIP1 level was an independent indicator for both TTR (hazard ratio [HR] 2.57, 95% CI 1.58–4.17, P < 0.001) and OS (HR 2.48, 95% CI 1.46–4.20, P = 0.001; Tables 2, 3). Moreover, in patients with low AFP levels (≤ 400 ng/ml), STIP1 was significantly correlated with both shorter TTR and OS (both P < 0.001; Figure 3F). Also, patients with high pretreatment STIP1 levels had higher recurrence (81.97 vs. 30.00%) and death (67.21 vs. 31.67%) rates in the low-AFP subgroup (Figure 3G). Pretreatment STIP1 retained its prognostic value in conventional low-risk subgroups such as single tumors, small tumor size, well differentiation, or complete encapsulation (all P < 0.050; Figure S1).
Table 2
| Variables | Recurrence | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Gender (male vs. female) | 1.15 (0.66–1.99) | 0.627 | 1.00 (0.56–1.78) | 0.994 |
| Age (>50 vs. ≤50 years) | 0.82 (0.55–1.22) | 0.319 | 0.85 (0.55–1.32) | 0.471 |
| HBsAg (positive vs. negative) | 1.79 (0.99–3.21) | 0.050 | 1.84 (0.97–3.50) | 0.064 |
| Cirrhosis (yes vs. no) | 5.45 (0.76–39.13) | 0.092 | 4.50 (0.63–32.34) | 0.135 |
| ALT (>40 vs. ≤40 U/L) | 1.39 (0.91–2.14) | 0.128 | 1.36 (0.87–2.10) | 0.171 |
| AFP (>400 vs. ≤400 ng/ml) | 1.15 (0.73–1.81) | 0.550 | 1.28 (0.79–2.07) | 0.313 |
| Tumor size (>5 vs. ≤5 cm) | 1.04 (0.67–1.60) | 0.871 | 0.94 (0.59–1.51) | 0.803 |
| Tumor number (multiple vs. single) | 4.01 (2/48–6.53) | <0.001 | 3.71 (2.19–6.27) | <0.001 |
| Microvascular invasion (present vs. absent) | 4.59 (3.00–7.03) | <0.001 | 4.12 (2.60–6.53) | <0.001 |
| Tumor encapsulation (incomplete vs. complete) | 2.86 (1.92–4.29) | <0.001 | 2.24 (1.45–3.47) | <0.001 |
| Tumor differentiation (III–IV vs. I–II) | 2.30 (1.54–3.44) | <0.001 | 2.20 (1.43–3.39) | <0.001 |
| Pretreatment serum STIP1 (>83.43 vs. ≤83.43 ng/ml) | 2.97 (1.91–4.60) | <0.001 | 2.60 (1.62–4.16) | <0.001 |
Univariate Cox proportional regression analysis of factors associated with recurrence and overall survival after curative resection.
HR, hazard ratio; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AFP, α-fetoprotein; STIP1, Stress Induced Phosphoprotein 1.
Table 3
| Variables | Recurrence | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Tumor number (multiple vs. single) | 3.32 (1.92–5.72) | <0.001 | 2.45 (1.40–4.28) | 0.002 |
| Microvascular invasion (present vs. absent) | 2.38 (1.49–3.80) | <0.001 | 1.91 (1.16—.13) | 0.011 |
| Tumor encapsulation (incomplete vs. complete) | 1.43 (0.91–2.25) | 0.123 | 1.19 (0.74–1.91) | 0.483 |
| Tumor differentiation (III–IV vs. I–II) | 1.40 (0.91–2.17) | 0.127 | 1.43 (0.90–2.27) | 0.128 |
| Pretreatment serum STIP1 (>83.43 vs. ≤83.43 ng/ml) | 2.57 (1.58–4.17) | <0.001 | 2.48 (1.46–4.20) | 0.001 |
Multivariate Cox proportional regression analysis of factors associated with recurrence and overall survival after curative resection.
HR, hazard ratio; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AFP, α-fetoprotein; STIP1, Stress Induced Phosphoprotein 1.
Prognostic Value of Pretreatment STIP1 Level in Irresectable HCC
In the TACE group, patients with high pretreatment STIP1 levels (>112.06 ng/ml) had significantly shorter TTP (median 8.23 vs. 16.27 months, P = 0.001) and OS (median 23.70 months vs. not reached, P < 0.001) than those who had low pretreatment STIP1 levels (≤ 112.06 ng/ml) (Figure 3H). In addition, patients with high pretreatment STIP1 had higher progression (95.24 vs. 77.03%) and death rates (76.19 vs. 45.85%; Figure 3I). Cox regression analysis revealed that high pretreatment STIP1 level was an independent indicator for both TTP (HR 1.61, 95% CI 1.16–2.24, P = 0.005) and OS (HR 1.88, 95% CI 1.25–2.82, P = 0.002; Tables 4, 5) in the TACE group. In addition, in patients with low AFP levels (≤ 400 ng/ml), STIP1 was significantly correlated with both shorter TTP (P = 0.001) and OS (P = 0.014; Figure 3J). Also, patients with high pretreatment STIP1 levels had higher progression (93.10 vs. 69.57%) and death (70.69 vs. 39.13%) rates in the low-AFP subgroup (Figure 3K). Additionally, high pretreatment STIP1 was significantly associated with MVI (P < 0.001) and incomplete tumor encapsulation (P = 0.005; Table 1).
Table 4
| Variables | Progression | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Gender (male vs. female) | 0.97 (0.60–1.55) | 0.887 | 1.25 (0.68–2.27) | 0.473 |
| Age (>50 vs. ≤50 years) | 0.79 (0.57–1.08) | 0.134 | 0.65 (0.45–0.94) | 0.023 |
| HBsAg (positive vs. negative) | 1.23 (0.76–2.00) | 0.398 | 1.85 (0.93–3.70) | 0.080 |
| Cirrhosis (yes vs. no) | 1.23 (0.68–2.21) | 0.499 | 1.99 (0.88–4.54) | 0.100 |
| ALT (>40 vs. ≤40 U/L) | 0.96 (0.70–1.32) | 0.804 | 0.97 (0.66–1.41) | 0.857 |
| AFP (>400 vs. ≤400 ng/ml) | 1.54 (1.12–2.11) | 0.008 | 1.52 (1.05–2.20) | 0.026 |
| Tumor size (>5 vs. ≤5 cm) | 1.25 (0.87–1.80) | 0.231 | 1.18 (0.77–1.80) | 0.456 |
| Pretreatment serum STIP1 (>112.06 vs. ≤112.06 ng/ml) | 1.69 (1.22–2.35) | 0.002 | 1.95 (1.30–2.91) | 0.001 |
Univariate Cox proportional regression analysis of factors associated with recurrence and overall survival after TACE.
HR, hazard ratio; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AFP, α-fetoprotein; STIP1, Stress Induced Phosphoprotein 1.
Table 5
| Variables | Progression | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age (>50 vs. ≤50 years) | Not applicable | 0.74 (0.51–1.08) | 0.116 | |
| AFP (>400 vs. ≤400 ng/ml) | 1.44 (1.05–1.98) | 0.025 | 1.46 (1.10–2.12) | 0.046 |
| Pretreatment serum STIP1 (>112.06 vs. ≤112.06 ng/ml) | 1.61 (1.16–2.24) | 0.005 | 1.88 (1.25–2.82) | 0.002 |
Multivariate Cox proportional regression analysis of factors associated with progression and overall survival after TACE.
HR, hazard ratio; HBsAg, hepatitis B surface antigen; ALT, alanine aminotransferase; AFP, α-fetoprotein; STIP1, Stress Induced Phosphoprotein 1.
Prognostic Value of Dynamic Changes of Serum STIP1 in Patients With Resectable HCC
We further explored the dynamic changes in STIP1 during the perioperative period in 169 patients who received curative resection. STIP1 levels were significantly decreased 1 month after surgery (P < 0.001; Figure 4A). Similarly, the percentage of patients with high STIP1 was also reduced after surgery (53.42 vs. 24.22%). These patients were further divided into four groups based on perioperative STIP1 levels: Group I, both high for pretreatment and post-treatment (n = 25); Group II, pretreatment high and post-treatment low (n = 61); Group III, pretreatment low and post-treatment high (n = 13); and Group IV, both low pretreatment and post-treatment (n = 62). Recurrence rates were 92.00, 72.13, 76.92, and 30.05%, respectively (Figure 4B). Median TTR was significantly shorter for Group I than for Group II (P = 0.009), Group III (P = 0.041), and Group IV (P < 0.001). Meanwhile, patients in Group II and Group III also had significantly shorter TTR than patients in Group IV (both P < 0.001). No significant difference in TTR between patients in Group II and Group III was observed (P = 0.982; Figure 4B). Death rates were 84.00, 60.66, 61.54, and 27.42%, respectively (Figure 4C). Median OS was significantly shorter for Group I than for Group II (P < 0.001), Group III (P = 0.046), and Group IV (P < 0.001). Also, patients in Group II and Group III had significantly shorter OS than patients in Group IV (both P < 0.001). No significant difference in OS between patients in Group II and Group III was observed (P = 0.926; Figure 4C).
Figure 4
Prognostic Value of Dynamic Changes of Serum STIP1 in Patients With Irresectable HCC
STIP1 levels showed a significant reduction after TACE (P < 0.001) and the percentage of patients with high STIP1 was also decreased after TACE (58.66 vs. 38.55%; Figure 4D). All 179 patients in the TACE group were divided into four groups based on their pre- and post-TACE STIP1 levels. Progression rates were 98.08, 92.45, 94.12, and 71.93% for these four groups, respectively (Figure 4E). Median TTP was significantly shorter in Group I than in Group II (P = 0.016) and Group IV (P < 0.001), and significantly shorter TTP was observed in Group III when compared with Group II and IV (both P < 0.050). Patients in Group II also had significantly shorter TTP than patients in Group IV (P = 0.010). Death rates were 82.69, 69.81, 76.47, and 36.84%, respectively. Median OS was significantly shorter in Group I than in Group II (P = 0.016) and Group IV (P < 0.001), and significantly shorter OS was observed in Group III when compared with Group II and IV (both P < 0.050; Figure 4F). Patients in Group II also had significantly shorter OS than patients in Group IV (P = 0.005).
Post-TACE but Not Pre-TACE STIP1 Level as a Promising Marker for Predicting Tumor Response to Single TACE Treatment
We first observed the single TACE response rate (defined as PR+CR according to the definition of objective response rate) in four groups stratified by peri-TACE STIP1 levels. Response rates were 57.69, 83.02, 29.14, and 78.95%, respectively (Figure 5A). Further investigations revealed that pre-TACE STIP1 levels showed no significant difference between responsive and non-responsive patients (P = 0.669), whereas post-TACE STIP1 levels were significantly decreased in responsive HCC patients (P < 0.001; Figure 5B). Multivariate logistic regression analysis indicated that post-TACE STIP1 level was the most powerful independent indicator for predicting response (odds ratio 21.09, 95% CI 7.37–60.23, P < 0.001; Table S1). Consistently, ROC curve analysis demonstrated post-TACE STIP1 had the largest AUC-ROC (AUC = 0.767) for predicting response among all variates investigated (Figure 5C). However, post-TACE STIP1 level showed no correlation with baseline AFP level or baseline total tumor size (both P > 0.050; Figures 5D,E).
Figure 5
Pretreatment STIP1 Level as a Novel Indicator for Predicting MVI in HCC
Among all patients enrolled in the resection group, 66 (40.99%) patients encountered MVI. Pretreatment STIP1 levels were significantly increased in patients with MVI (P < 0.001; Figure 6A). Moreover, patients with high STIP1 had higher MVI-positive rates (55.81 vs. 24.00%; Figure 6B). ROC analysis revealed that pretreatment STIP1 exhibited the largest AUC (AUC = 0.644) among all variables explored (Figure 6C and Table S2). However, other involved predictors including AFP (AUC = 0.521), ALT (AUC = 0.456), differentiation (AUC = 0.611), tumor number (AUC = 0.602), and tumor size (AUC = 501) showed unsatisfactory performance. We further investigated the prognostic role of STIP1 in the MVI-absent subgroup. Similarly, pretreatment STIP1 was also significantly correlated with both shorter TTR (P < 0.001) and OS (P = 0.012; Figure 6D) in patients without MVI. Concordantly, MVI-absent patients with high pretreatment STIP1 levels had higher recurrence (60.53 vs. 22.81%) and death (44.74 vs. 21.57%) rates (Figure 6E).
Figure 6
Discussion
Despite the great improvements made in last two decades, prognosis of HCC remains unsatisfactory (3). Such an embarrassing situation might be partially attributed to lack of a promising and reliable biomarker for outcome prediction and real-time surveillance of tumor progression. Here, we demonstrated serum STIP1 could serve as a novel biomarker to discriminate HCC patients with high risk of developing progression. Moreover, monitoring peri-treatment dynamic changes of STIP1 could provide useful information for predicting long-term prognosis after treatment. Importantly, post-TACE STIP1 level was identified as a powerful indicator to reflect the response to TACE. Specifically, our data also confirmed the clinical utility of STIP1 detection in predicting MVI.
As a crucial co-chaperone of HSP90 complex, STIP1 was reported to execute its elemental function with HSP90, resulting in rapid cancer progression (11). STIP1 was preferentially expressed in cancerous tissues of various solid tumors, including HCC, and high STIP1 expression was closely associated with dismal outcomes (11, 18, 21, 29). Moreover, functional assays confirmed STIP1 as a vital pro-oncogene during carcinogenesis process (30, 31). Interestingly, recent studies demonstrated STIP1 could be secreted by tumor cells and act as a critical cytokine to regulate malignant phenotype (17). STIP1 has been identified as crucial regulator of HCC progression. Previous studies have demonstrated that STIP1 promoted metastases foci formation via activating snail transcription and subsequently epithelial-to-mesenchymal transition in an HSP-dependent manner (31). Moreover, it could provoke HCC progression via interaction with Axin and DVL2 to activate beta-catenin signaling (29). Of note, secretory form STIP1 could stimulate HCC progression in an autocrine manner (21), which led us to raise the hypothesis that serum STIP1 might be a potential biomarker for predicting prognosis of HCC. Here, we showed that serum STIP levels were significantly elevated in HCC patients compared with either CHB patients or HDs. Intriguingly, STIP1 levels increased with HCC progression, suggesting the potential role of STIP1 in HCC diagnosis. Further investigation demonstrated pretreatment STIP1 level was an independent indicator for both tumor progression and survival, regardless of therapeutic approach. Clinically, AFP is currently the mostly widely used serum biomarker for evaluating prognosis. However, monitoring progression in low-AFP subgroups remains a challenge (22). We found serum STIP1 retained its prognostic value in low-AFP subgroups, suggesting STIP1 might be a useful supplement to AFP detection to achieve more accuracy in identifying patients with dismal outcomes. Together, our data indicated pretreatment STIP1 is a powerful and feasible biomarker for predicting prognosis in HCC.
Monitoring dynamic changes in tumor biomarkers during the peri-treatment period could provide critical information to reflect the disease status after treatment. Our data indicated serum STIP1 levels were dramatically decreased after treatment, and patients whose STIP1 level remained high or became high after treatment suffered significantly worse long-term prognosis in both the resection and TACE groups. Because tumors were completely removed in patients who underwent curative resection, dynamic changes in STIP1 might reflect the micro-dissemination that could not be observed during operation. Thus, perioperative dynamic changes in STIP1 might be a valuable basis for the application of adjuvant interventions such as TACE or sorafenib after surgery. Meanwhile, for patients who received TACE, the predictive value of monitoring peri-TACE dynamic changes in STIP1 for long-term survival might reflect the intrinsic characteristics of HCC toward hypoxia and cytotoxicity. Thus, more importantly, our findings provide a more powerful and reliable basis to precisely predict the outcomes after TACE, as evidenced by greater AUC-ROC (Figure S2).
TACE is recommended as the first therapeutic approach for intermediate-HCC patients by BCLC criteria (32). However, heterogeneous responses to TACE were widely observed in clinical practice (33). Unfortunately, conventional pathological parameters for predicting treatment response were not available for patients in this study who received TACE due to difficulties in obtaining biopsy samples. Meanwhile, serum biomarkers are considered an ideal tool to monitor treatment response to TACE with the advantages of easy acquisition and noninvasiveness. Moreover, serum detection provides a safer and more convenient approach than imaging scans with the advantage of non-exposure to radiation. Here, we found post-TACE but not pre-TACE STIP1 levels were closely associated with the objective response rate after single TACE treatment. Further ROC curve analysis demonstrated the satisfactory performance of post-TACE STIP1 level for predicting OR. Notably, post-TACE STIP1 level showed no correlation with baseline tumor size or AFP level, suggesting the universal use of post-TACE STIP1 level in evaluating response to single TACE treatment, regardless of baseline HCC status. Together, our data indicated that post-TACE STIP1 detection was a promising non-invasive method with strong predictive power toward therapeutic response.
Accumulating clinical evidence confirmed the presence of MVI as a significant risk indicator for worse outcomes in HCC (34). Clinically, the presence of MVI acts as a crucial indicator for selecting appropriate therapeutic intervention for HCC patients (35). Unfortunately, most of the risk factors associated with MVI are pathological characteristics that can only be determined in resected samples or biopsy, posing a problem in routine clinical practice (36, 37). Therefore, identification of serum biomarkers for predicting MVI before treatment might improve HCC management. Here, we reported that patients with high pretreatment serum STIP1 levels had a high possibility of harboring MVI, and high STIP1 was confirmed as an independent predictor for MVI. Moreover, we found the predictive performance of STIP1 was stronger than other biomarkers such as AFP, tumor size, and tumor number. Thus, our findings demonstrate a powerful tool for providing accurate and useful information for MVI prediction in HCC, enabling early clinical decisions to tailor appropriate therapeutic approaches for individualized therapy in HCC.
There are several limitations in our present study. First, it was a single-centered, retrospective study. Therefore, prospective and external validations are further needed in the future. Second, most patients enrolled had HBV backgrounds, which greatly differed from the patients in United States or Europe (38). We could not exclude the possibility that the predictive value of serum STIP1 was not applicable in HCC patients with other etiology backgrounds, and further confirmation is also needed. Finally, despite the satisfactory performance of STIP1, more investigations should be conducted to optimize the best cutoff or generate novel index containing STIP1 and other serum biomarkers to improve the discrimination power.
Conclusions
In summary, our data demonstrated the prognostic significance of serum STIP1 in HCC. Importantly, dynamic changes in STIP1 were found to exert great significance in reflecting treatment response, especially in predicting objective response to single TACE intervention. Moreover, our data indicated STIP1 detection as a useful tool for predicting MVI before surgery with the advantages of convenience and accuracy. Integration of serum STIP1 detection into HCC management might facilitate early clinical decision-making to improve the prognosis of HCC patients in the future.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.
Ethics statement
The studies involving human participants were reviewed and approved by Research Ethics Committee of Zhongshan Hospital. The patients/participants provided their written informed consent to participate in this study.
Author contributions
X-LM, GL, and R-QL: conceptualization. X-LM, S-HX, M-JY, M-LW, and W-GT: methodology. GL and R-QL: validation, visualization, supervision, and project administration. X-LM, M-LW, and M-JY: formal analysis. X-LM and M-JY: investigation. W-GT, GL, and R-QL: resources. X-LM, GL, and R-QL: data curation. X-LM: writing—original draft preparation. All authors: writing (review and editing). W-GT, GL, and R-QL: funding acquisition.
Funding
This research was funded by National Natural Science Foundation of China, grant number 81572552, 81772774, 81772808, 8180101167, and 31771472; the project from Shanghai Science and Technology Commission, grant number 17411963500 and 17411951000; the construction project for important weak discipline from Shanghai Municipal Health Commission, grant number 2015ZB0204; the project from Minhang Hospital (2018MHJ05), the project from Minhang Science and Technology Commission (2019MHZ077), and the fusion grant of Minhang Hospital-College of Pharmacy, Fudan University (RO-MY201805).
Acknowledgments
We thank Prof. Ning Ren and Dr. Pei-Yao Fu from the Department of Liver Surgery, Zhongshan Hospital, Fudan University, for their help in evaluating objective response after TACE.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer JZ declared a shared affiliation, with no collaboration, with the authors to the handling editor at the time of review.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.00511/full#supplementary-material
- STIP1
stress-induced-phosphoprotein 1
- HCC
hepatocellular carcinoma
- TACE
transcatheter arterial chemoembolization
- ELISA
enzyme-linked immunosorbent assay
- ROC
receiver operating characteristic
- OR
objective response
- CHB
chronic hepatitis B
- MVI
microvascular invasion
- OS
overall survival
- TTR
time to recurrence
- TTP
time to progression
- BCLC
Barcelona Clinic Liver Cancer
- HSP
heat shock protein
- CT
computed tomography
- MRI
magnetic resonance imaging
- CR
complete response
- PR
partial response
- SD
stable disease
- PD
progressive disease.
Abbreviations
References
1.
ZhuXDSunHC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. (2019) 12:110. 10.1186/s13045-019-0794-6
2.
HouJZhangHSunBKarinM. The immunobiology of hepatocellular carcinoma in humans mice: basic concepts therapeutic implications. J Hepatol. (2019) 72:167–82. 10.1016/j.jhep.2019.08.014
3.
YangJDHainautPGoresGJAmadouAPlymothARobertsLR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. (2019) 16:589–604. 10.1038/s41575-019-0186-y
4.
TohTBLimJJHooiLRashidMBMAChowEK. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma. J Hepatol. (2019) 72:104–18. 10.1016/j.jhep.2019.08.035
5.
BonninMFaresNTestoniBEstornesYWeberKVanbervlietBet al. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis. J Hepatol. (2019) 71:763–72. 10.1016/j.jhep.2019.05.031
6.
YauTHsuCKimTYChooSPKangYKHouMMet al. Nivolumab in advanced hepatocellular carcinoma: sorafenib-experienced Asian cohort analysis. J Hepatol. (2019) 71:543–52. 10.1016/j.jhep.2019.05.014
7.
ZhangXPLiuYCChenZHSunJXWangKChaiZTet al. Postoperative adjuvant transarterial chemoembolization improves outcomes of hepatocellular carcinoma associated with hepatic vein invasion: a propensity score matching analysis. Ann Surg Oncol. (2019) 26:1465–73. 10.1245/s10434-019-07223-z
8.
LeYShenJXZhangYFHeMKKanAChenHLet al. Transarterial chemoembolization related to good survival for selected patients with advanced hepatocellular carcinoma. J Cancer. (2019) 10:665–71. 10.7150/jca.28528
9.
WangQXiaDBaiWWangESunJHuangMet al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J Hepatol. (2019) 70:893–903. 10.1016/j.jhep.2019.01.013
10.
LiuSLiHGuoLZhangBZhouBZhangWet al. Tumor size affects efficacy of adjuvant transarterial chemoembolization in patients with hepatocellular carcinoma and microvascular invasion. Oncologist. (2019) 24:513–20. 10.1634/theoncologist.2018-0305
11.
ZhangSShaoJSuF. Prognostic significance of STIP1 expression in human cancer: a meta-analysis. Clin Chim Acta. (2018) 486:168–76. 10.1016/j.cca.2018.07.037
12.
TsaiCLChaoAJungSMTsaiCNLinCYChenSHet al. Stress-induced phosphoprotein-1 maintains the stability of JAK2 in cancer cells. Oncotarget. (2016) 7:50548–63. 10.18632/oncotarget.10500
13.
XuCPLiXHuYJCuiZWangLLiangLet al. Quantitative proteomics reveals ELP2 as a regulator to the inhibitory effect of TNF-α on osteoblast differentiation. J Proteomics. (2015) 114:234–46. 10.1016/j.jprot.2014.11.002
14.
ChoHKimSShinHYChungEJKitanoHHyonet al. Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer. Genes Chromosomes Cancer. (2014) 53:277–88. 10.1002/gcc.22136
15.
van SimaeysDTurekDChampanhacCVaizerJSefahKZhenJet al. Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment. Anal Chem. (2014) 86:4521–7. 10.1021/ac500466x
16.
TsaiCLTsaiCNLinCYChenHWLeeYSChaoAet al. Secreted stress-induced phosphoprotein 1 activates the ALK2-SMAD signaling pathways and promotes cell proliferation of ovarian cancer cells. Cell Rep. (2012) 2:283–93. 10.1016/j.celrep.2012.07.002
17.
WangTHChaoATsaiCLChangCLChenSHLeeYSet al. Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation. Mol Cell Proteomics. (2010) 9:1873–84. 10.1074/mcp.M110.000802
18.
HuangLZhaiECaiSLinYLiaoJJinHet al. Stress-inducible Protein-1 promotes metastasis of gastric cancer via Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. (2018) 37:6. 10.1186/s13046-018-0676-8
19.
KrafftUTschirdewahnSHessJHarkeNNHadaschikBANyirádyPet al. STIP1 tissue expression is associated with survival in chemotherapy-treated bladder cancer patients. Pathol Oncol Res. (2019). [Epub ahead of print]. 10.1007/s12253-019-00689-y.
20.
WangHSTsaiCLChangPYChaoAWuRCChenSHet al. Positive associations between upregulated levels of stress-induced phosphoprotein 1 and matrix metalloproteinase-9 in endometriosis/adenomyosis. PLoS ONE. (2018) 13:e0190573. 10.1371/journal.pone.0190573
21.
ChenZXuLSuTKeZPengZZhangNet al. Autocrine STIP1 signaling promotes tumor growth and is associated with disease outcome in hepatocellular carcinoma. Biochem Biophys Res Commun. (2017) 493:365–72. 10.1016/j.bbrc.2017.09.016
22.
MaXLJiangMZhaoYWangBLShenMNZhouYet al. Application of serum Annexin A3 in diagnosis, outcome prediction and therapeutic response evaluation for patients with hepatocellular carcinoma. Ann Surg Oncol. (2018) 25:1686–94. 10.1245/s10434-018-6402-0
23.
ZhangXPZhouTFWangZHZhangFZhongCQHuYRet al. Association of preoperative hypercoagulability with poor prognosis in hepatocellular carcinoma patients with microvascular invasion after liver resection: a multicenter study. Ann Surg Oncol. (2019) 26:4117–25. 10.1245/s10434-019-07504-7
24.
YohTSeoSTauraKIguchiKOgisoSFukumitsuKet al. Surgery for recurrent hepatocellular carcinoma: achieving long-term survival. Ann Surg. (2019). [Epub ahead of print]. 10.1097/SLA.0000000000003358.
25.
LiJWangQLeiZWuDSiAWangKet al. Adjuvant transarterial chemoembolization following liver resection for intrahepatic cholangiocarcinoma based on survival risk stratification. Oncologist. (2015) 20:640–7. 10.1634/theoncologist.2014-0470
26.
GuoWYangXRSunYFShenMNMaXLWuJet al. Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res. (2014) 20:4794–805. 10.1158/1078-0432.CCR-14-0251
27.
LoosenSHSchulze-HagenMLeyhCBenzFVucurMKuhlCet al. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies. Int J Mol Sci. (2018) 19:1766. 10.3390/ijms19061766
28.
YoonSMRyooBYLeeSJKimJHShinJHAnJHet al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. (2018) 4:661–9. 10.1001/jamaoncol.2017.5847
29.
LuoXLiuYMaSLiuLXieRLiMet al. STIP1 is over-expressed in hepatocellular carcinoma and promotes the growth and migration of cancer cells. Gene. (2018) 662:110–7. 10.1016/j.gene.2018.03.076
30.
XuWRaoQAnYLiMZhangZ. Identification of biomarkers for Barcelona clinic liver Cancer staging and overall survival of patients with hepatocellular carcinoma. PLoS ONE. (2018) 13:e0202763. 10.1371/journal.pone.0202763
31.
SuTLiaoJDaiZXuLChenSWangYet al. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene. (2018) 37:3514–27. 10.1038/s41388-018-0169-4
32.
LlovetJMMontalRSiaDFinnRS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. (2018) 15:599–616. 10.1038/s41571-018-0073-4
33.
RaoulJLFornerABolondiLCheungTTKloecknerRde BaereT. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. (2019) 72:28–36. 10.1016/j.ctrv.2018.11.002
34.
FinnRSZhuAXFarahWAlmasriJZaiemFProkopLJet al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology. (2018) 67:422–35. 10.1002/hep.29486
35.
ZhangXLiJShenFLauWY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. (2018) 33:347–54. 10.1111/jgh.13843
36.
HyunSHEoJSSongBILeeJWNaSJHongIKet al. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using (18)F-FDG PET/CT: a multicenter retrospective cohort study. Eur J Nucl Med Mol Imaging. (2018) 45:720–6. 10.1007/s00259-017-3880-4
37.
ErstadDJTanabeKK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. (2019) 26:1474–93. 10.1245/s10434-019-07227-9
38.
HuBYangXRXuYSunYFSunCGuoWet al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. (2014) 20:6212–22. 10.1158/1078-0432.CCR-14-0442
Summary
Keywords
hepatocellular carcinoma, resection, TACE, prognosis, STIP1, serum biomarker, microvascular invasion
Citation
Ma X-L, Tang W-G, Yang M-J, Xie S-H, Wu M-L, Lin G and Lu R-Q (2020) Serum STIP1, a Novel Indicator for Microvascular Invasion, Predicts Outcomes and Treatment Response in Hepatocellular Carcinoma. Front. Oncol. 10:511. doi: 10.3389/fonc.2020.00511
Received
28 November 2019
Accepted
23 March 2020
Published
30 April 2020
Volume
10 - 2020
Edited by
Marco Scarpa, University Hospital of Padua, Italy
Reviewed by
Jian Zhou, Fudan University, China; Eva Andreuzzi, Aviano Oncological Reference Center (CRO), Italy
Updates
Copyright
© 2020 Ma, Tang, Yang, Xie, Wu, Lin and Lu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Guo Lin guolin500@hotmail.comRen-Quan Lu lurenquan@126.com
This article was submitted to Surgical Oncology, a section of the journal Frontiers in Oncology
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.